Coagulopathy in COVID-19

Area of Science:

• Hematology
• Infectious Diseases
• Critical Care Medicine

Background:

• The COVID-19 pandemic presents significant global health challenges.
• Severe COVID-19 cases frequently exhibit coagulopathy, marked by disseminated intravascular coagulation (DIC)-like intravascular clot formation.
• Understanding COVID-19-associated coagulopathy is crucial for managing severe illness.

Purpose of the Study:

• To explore the utility of coagulation tests in distinguishing severe COVID-19 cases.
• To characterize the clinical presentation and hemostatic biomarker changes in COVID-19-associated coagulopathy.
• To compare COVID-19 coagulopathy with sepsis-associated coagulopathy/DIC.

Main Methods:

• Analysis of clinical presentations in severely ill COVID-19 patients.
• Evaluation of hemostatic biomarkers, including D-dimer and fibrin/fibrinogen degradation products.
• Comparison of coagulation parameters (prothrombin time, activated partial thromboplastin time, antithrombin activity, platelet count) with bacterial sepsis-associated coagulopathy/DIC.

Main Results:

• COVID-19-associated coagulopathy primarily manifests as organ dysfunction, with less frequent bleeding events.
• Elevated D-dimer and fibrin/fibrinogen degradation products indicate significant fibrin formation.
• Compared to sepsis-associated coagulopathy/DIC, COVID-19 shows less frequent prolongation of PT/aPTT, decreased antithrombin activity, and lower incidence of thrombocytopenia.
• Potential mechanisms include dysregulated immune responses, cytokine storms, lymphocyte cell death, hypoxia, and endothelial damage.

Conclusions:

• Coagulation tests may aid in identifying severe COVID-19.
• COVID-19-associated coagulopathy differs from sepsis-induced coagulopathy/DIC in its clinical and laboratory features.
• Further research is needed to elucidate the exact mechanisms and address uncertainties regarding thrombosis incidence and optimal anticoagulation strategies in COVID-19.